2019 MOTIVATE Course 3: Prevention of MOH

2019 MOTIVATE Course 3: Prevention of MOH

Current Status
Not Enrolled
Get Started
This course is currently closed

1 Category 2 points with the RACGP

1 Core PDP point

All participants will be awarded a certificate of completion for self-reporting to other colleges

Duration: 30 minutes

Treatment of MOH may be difficult, and so it is important for patients to understand how to prevent this condition in the first place. As a healthcare professional, learn how to recognise patients at risk of MOH and educate them on how to avoid falling into the cyclical trap of overusing their headache medications.

Learning objectives:
Upon completing this course, participants will be able to:

  • List the classes of medications used to prevent chronic migraine;
  • Differentiate treatment for infrequent severe headaches and frequent episodic headaches;
  • Outline a plan to address the most common barriers to managing MOH and codeine-withdrawal effects;
  • Explain the interdisciplinary (between GPs and pharmacists) management of MOH;
  • Put a reminder system in place that would make use of the different monitoring strategies (e.g. headache diaries, support from both GPs and pharmacists, use of clinical measures of headache-related disability) to assess patient compliance to preventive treatment.
  • Associate Professor Richard Stark, Alfred Hospital, Melbourne, Victoria
  • Professor Mieke Van Driel, School of Medicine, University of Queensland, Herston, Queensland
  • Associate Professor Treasure McGuire, School of Pharmacy, University of Queensland, Queensland; Faculty of Health Sciences & Medicine, Bond University, Gold Coast, Queensland
  • Dr Brett McFarlane, The Australian College of Pharmacy, Canberra, Australian Capital Territory
  • Professor Deborah Turnbull, School of Psychology, University of Adelaide, South Australia
    • Royal Australian College of General Practitioners:
      • 1 Category Two QI&CPD points
      • Activity no. 109006
    • Australian College of Rural and Remote Medicine:
      • 1 Core PDP point
      • Activity no. 10380
    • Pharmacists and nurses are invited to access this continuing professional development activity. At the end, a certificate may be downloaded as proof of completion.

Dr Lara Mihaljevic
General Practitioner
Drummoyne Medical Centre, Victoria Road, Drummoyne, NSW

  • Faculty
    • Associate Professor Richard Stark: Co-authored a clinical paper sponsored by Pfizer on the safety of eletriptan. Between 2012 and 2014 received consulting and lecture fees from Allergan and lecture fees from MSD on chronic migraine
    • Professor Mieke Van Driel: No conflict of interest
    • Associate Professor Treasure McGuire: No conflict of interest
    • Dr Brett McFarlane: No conflict of interest
    • Professor Deborah Turnbull: Received research grants and co-authored papers on hypertension sponsored by pharmaceutical companies, including Pfizer Pty. Ltd., between 1999 and 2006
  • GP reviewer
    • Dr Lara Mihaljevic: No conflict of interest
  • Non-faculty: employees of In Vivo Academy involved in producing the content of this course, Aishwarya Sridharan, Tina Garcia, Monica Kurniawan and Lisa Sullivan, declare no conflict of interest.